(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics ...

Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

Gaithersburg’s Novavax has secured formal regulatory approval for its Covid vaccine. It's a major win, after the FDA delayed ...

Novavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.